Australia's CSL knocked by Pentagon flu policy shift, stock sinks to 2017 low
By Rajasik Mukherjee April 23 (Reuters) - Australian biotech giant CSL extended losses on Thursday, lingering near decade lows, after the U.S. military scrapped its flu vaccine mandate, dealing another blow to the drugmaker as it grapples with a prolonged earnings slump.